Enter a keyword or phrase to search all pages in this section:


Advanced search

Archive:

Looking for a previously published document in this section?

Press release: Reckitt Benckiser (UK) Ltd recalls all Nurofen Plus Tablets

Press Release

Date: 26 August 2011
Time: 20:15
Subject: Reckitt Benckiser (UK) Ltd recalls all Nurofen Plus Tablets
Contact: Press Office 020 3080 7651
or press.office@mhra.gsi.gov.uk
Out-of-hours 07770 446 189

Reckitt Benckiser (UK) Ltd has received further reports of rogue blister strips in cartons of two additional batches of Nurofen Plus tablets. One of the new batches contained Seroquel XL 50mg tablets and one contained the Pfizer product Neurontin 100mg capsules.

Reckitt Benckiser (UK) Ltd is now recalling all remaining unexpired stock of Nurofen Plus tablets in any pack size as a precautionary measure.

Ian Holloway from the Medicines and Healthcare products Regulatory Agency (MHRA)’s Defective Medicines Report Centre (DMRC) said, “People should check to see if they have any packets of Nurofen Plus. If you do, return them to your nearest pharmacy”.

Notes to Editor

  1. The MHRA has today issued a Class 1 Drug Alert to healthcare professionals.
  2. Nurofen Plus tablets are pharmacy only status. The company that holds the licence is Reckitt Benckiser (UK) Ltd. The medicine is used as a painkiller for the short-term treatment of acute, moderate pain which is not relieved by paracetamol, ibuprofen or aspirin alone. It contains codeine.
  3. Seroquel XL 50mg tablets are prescription-only. The company that holds the original licence is AstraZeneca UK Ltd. The medicine is an anti-psychotic used to treat several illnesses such as schizophrenia, mania and bipolar depression.
  4. Neurontin 100mg capsules are prescription-only. The company that holds the original licence is Pfizer Limited. The medicine is used to treat epilepsy and peripheral neuropathic pain (i.e long-lasting pain caused by damage to the nerves).
Page last modified: 26 August 2011